Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Malaria medicine chloroquine inhibits tumor growth and metastases

12.08.2014

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors.

This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

The anti-cancer effect of the antimalarial agent chloroquine when combined with conventional chemotherapy has been well documented in experimental animal models. To date, it was assumed that chloroquine increases the sensitivity of cancer cells to chemotherapy by means of a direct effect on the cancer cells.

However, a recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand – thereby blocking cancer cell dissemination and metastasis– and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

Chloroquine is a well-known medicine with a good safety profile that has been in use since World War 2 for the treatment of malaria and certain auto-immune diseases, including rheumatoid arthritis. More recently, chloroquine has also been used in anti-cancer treatment. Chloroquine blocks autophagy, a process that cancer cells use to survive to anti-cancer treatments. Therefore, blocking autophagy would reduce the resistance of the cancer cells to chemotherapy.

Normalization of abnormal tumor blood vessels

Hannelore Maes from the team of Patrizia Agostinis (KU Leuven), together with Anna Kuchnio from the team of Peter Carmeliet (VIB-KU Leuven) have started a study to explain how chloroquine can strengthen the effect of anti-cancer treatments.

"Although it is assumed that chloroquine strengthens anti-cancer treatment by blocking autophagy, there is little in vivo evidence that this is the only way in which chloroquine works. In this study, we found that chloroquine not only has an effect on the growth of the cancer cells, but also makes the tumor environment less aggressive by normalizing the abnormal blood vessels in the tumor", says Patrizia Agostinis.

Peter Carmeliet: "Blood vessel normalization results in improved tumor perfusion. This reduces the aggressive nature of the cancer cells and means that the anti-cancer medicines are better able to reach the cancer cells, which makes chemotherapy more effective. In addition, tumor blood vessel normalization also increases the barrier function of the blood vessels, which reduces the access of cancer cells to the circulation – the most important transport system for the spreading of cancer cells to other tissues. Therefore, chloroquine can nip the metastatic spreading of cancer cells in the bud, which is the most important therapeutic goal in any tumor treatment."

Disadvantages do not outweigh the benefits – the impact of this study on the use of chloroquine in anti-cancer treatment

This study forms a new rationale for the use of chloroquine in anti-cancer treatment. With a view to clinical studies (tests on humans) it is important to note that the effects on the tumor vasculature were even observed at chloroquine concentrations that had little effect on autophagy in the cancer cells. This sheds new light on the therapeutic schedule for combination therapy with chloroquine, which could result in decreased toxicity. In other words, the same "old" medicine simultaneously targets the cancer cells themselves and the blood vessels with great efficiency.

Research teams

This research was conducted by the team of Patrizia Agostinis, Department of Cellular and Molecular Medicine, KU Leuven in collaboration with the team of Peter Carmeliet from the VIB Vesalius Research Center, KU Leuven.

Sooike Stoops | Eurek Alert!
Further information:
http://www.vb.be

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>